San Carlos, CA – According to filings with the U.S. Securities and Exchange Commission, Cage Bio is raising $15,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Nitin Joshi played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Cage Bio
CAGE Bio Inc. is a privately-held clinical-stage company exploiting its proprietary deep eutectic ionic liquid platform to develop novel products for dermatology, inflammation, and immunology. We have demonstrated delivery of a wide range of materials including small molecules, peptides, proteins and nucleic acids across the stratum corneum following topical administration with minimal impact on barrier functions and viability. This unprecedented flexibility in the choice of cations and anions enables us to engineer diverse ILs with tailor made properties for multiple therapeutic areas. Additionally, the inherent properties of such deep eutectic ILs as broad-spectrum antimicrobial agents in addition to exceptional solvation and permeation enhancement offer phenomenal opportunities in drug discovery and pharmaceutical space. Best-in-Class Platform for Immunodermatological Diseases. Our team has accumulated a vast amount of in vitro and in vivo evidence supporting the role of ILs in improving tissue-specific delivery of therapeutic entities into the skin. The platform we are developing can be used across multiple modalities and diseases, making them a valuable therapeutic platform.

To learn more about Cage Bio, visit http://cagebio.com/

Contact:
Nitin Joshi, Chief Executive Officer
650-996-1845
njoshi@califesciences.org
https://www.linkedin.com/in/nitin-joshi-35112b5/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved